Lebrikizumab Performs Well in AD Patients With Darker Skin Types
More than two-thirds of people with atopic dermatitis (AD) and darker skin tones treated with lebrikizumab showed improvements in skin clearance and itch relief, according to late-breaking results from a Phase 3 study are being presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego. Lebrikizumab (Ebglyss, Almirall), an interleukin-13 (IL-13) inhibitor, just received European […]